Report Overview

According to the deep-dive market study conducted by Growth Plus Reports, the global chronic hepatitis D therapeutics market is expected to register a revenue CAGR of 3.4% during the forecast period from 2022 to 2030.

Market Fundamentals

Hepatitis D is a liver infection brought on by the hepatitis D virus, commonly called "delta hepatitis" (HDV). Only those with hepatitis B and D virus infections develop hepatitis D. It may result in severe symptoms, life-long liver damage, and even death. Indigenous peoples, hemodialysis patients, and drug users are among the populations more prone to co-infect with HBV and HDV. Carriers of chronic HBV are susceptible to HDV infection. Individuals lacking immunity to HBV (due to a natural illness or vaccination with the hepatitis B vaccine) are at risk of contracting HBV, which increases their risk of contracting HDV.

Market Dynamic

Hepatitis D and B are becoming more common, and eating an imbalanced diet frequently will impact how quickly the market grows. The market revenue of hepatitis delta virus (HDV) infections will develop because of rising healthcare costs, increasing government financing, and expanding government and private group attempts to raise awareness of the disease. The market's revenue expansion will also be fueled by additional reasons, such as alcohol abuse and the increased prevalence of intravenous drug usage.

The high cost of care and hepatitis D consequences such as liver failure, cirrhosis, and hepatocellular cancer are the factors responsible for restraining the global chronic hepatitis D therapeutics market revenue growth. The market would face more difficulties because of a lack of knowledge about preventative measures. 

Market Ecosystem

The global chronic hepatitis D therapeutics market has been analyzed from three perspectives: drug class, distribution channel, and region.

Chronic Hepatitis D Therapeutics Market by Drug Class

[89768678]

Based on drug class, the global chronic Hepatitis D therapeutics market has been segmented into interferons and antiviral (nucleoside/nucleotide analogs). 

The interferons segment dominates the global chronic Hepatitis D therapeutics market in terms of large revenue share. This significant revenue share is attributed to it being the only medication used to treat HDV infection. Studies demonstrate a significant benefit of interferon monotherapy in managing the hepatitis D virus, expanding the market revenue share.

Chronic Hepatitis D Therapeutics Market by Distribution Channel

Based on distribution channels, the global chronic Hepatitis D therapeutics market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. 

The hospital pharmacy segment accounts for the most significant revenue in the global Chronic Hepatitis D Therapeutics Market. The preferred patient visit to the hospital for the proper professional diagnosis and treatment is the primary factor responsible for the hospital pharmacy segment to attain dominance in the global chronic hepatitis D therapeutics market in terms of revenue share.  Also, the availability of effective drugs in hospital pharmacies directly impacts market revenue growth.

Chronic Hepatitis D Therapeutics Market by Region 

Based on region, the global chronic Hepatitis D therapeutics market has been segmented into North America, Europe, Asia Pacific, and the rest of the world. 

North America, particularly the United States, dominates the global chronic hepatitis D therapeutics market with the largest revenue share, owing to the presence of prominent players and the considerable availability of branded and generic medications. Furthermore, high awareness levels for Hepatitis D diagnosis and treatment, availability of improved infrastructure, and favorable government initiatives are also expected to boost revenue growth of the market. Furthermore, the most common risk factor among people with new HBV infections is injecting drugs related to the opioid crisis. In the United States, rates of new HBV infections are highest among adults aged 30-59 years, reflecting low hepatitis D vaccination coverage among adults at risk.

Competitive Landscape

The prominent players operating in the global chronic hepatitis D therapeutics market are: - 

• F. Hoffmann-La Roche Ltd
• Vir Biotechnology
• Gilead Sciences, Inc.
• Eiger BioPharmaceuticals
• Janssen Pharmaceuticals, Inc.
• MYR Pharmaceuticals
• Hepatera Ltd.
• Antios Therapeutics, Inc.
• Merck Sharp & Dohme LLC

Strategic Developments

• In December 2022, the New Zealand Medicines and Medical Devices Safety Authority granted Bluejay Therapeutics regulatory approval to begin clinical trials of BJT-778 for treating chronic hepatitis B and chronic hepatitis D.
• In December 2022, lonafarnib, a first-in-class prenylation inhibitor, was tested in two regimens in patients with chronic HDV by Eiger Biopharmaceuticals, Inc.'s landmark Phase 3 D-LIVR trial (N=407): lonafarnib boosted with ritonavir alone (all-oral) and in combination with peginterferon alfa (combination).

Frequently Asked Questions About This Report